Solar energy co-op shines light on sustainability for Houston-area residents

join the club

A national solar energy organization is expanding in Houston to promote affordable sustainability. Getty Images

A nationwide nonprofit organization that focuses on promoting and educating on the use of solar energy, has chosen a local solar installer business for its West Houston co-op.

Solar United Neighbors, also known as SUN, was established in 2007 to represent the interests and needs of solar owners and those interested in going solar. The nonprofit has already helped more than 4,600 solar owners with over 35,000 kW installed. SUN is currently active in the Houston area with two co-ops formed.

The West Houston co-op, which opened in January of 2020, is open to residents and small businesses from Brookshire to Memorial City and Richmond. The co-op will be open to new members until July 31st. However, members have already chosen a local business, Sunshine Renewable Solutions to install solar panels for the group.

"It is an honor to be selected because we know how thoroughly the co-op reviewed each bid," says Sid Chandrashekar, vice president of sales and operations for Sunshine Renewable Solutions. "SUN's mission is aligned with ours when it comes to education efforts for solar energy, they use a community approach that is really informative to anybody that is interested in solar, and that's how we see ourselves more as educators and consultants."

Hanna Mitchell, the Texas Program Director for Solar United Neighbors says a co-op is a great way to reduce costs for local citizens looking to go solar. The co-op is free to join and there is no commitment to purchase panels.

"Through our education programs and events we hope to demystify the process of going solar," says Mitchell. "There is never any pressure to go forward with the installation, our main goal is to provide access to information so our members can make informed energy choices."

The West Houston co-op committee members chose Sunshine Renewable Solutions from seven other installers that put in a bid. Solar co-op members selected the local installer for their competitive pricing, battery options, and workmanship warranty.

Co-op member Joseph Garfunkel served on the committee who volunteered to review bids and choose an installer. Initially, he joined to learn more about the process to get solar in his home.

"I joined the West Houston Solar Co-op to learn more about the process for installing solar at my house, and to also to get an idea of the cost," says Garfunkel. "The solar co-op has been very helpful in providing webinars and other information describing the entire process."

The experts at SUN were able to hold events to further educate the members of the West Houston co-op of the benefits of solar investment, even after the rise of the coronavirus pandemic moved gatherings to virtual events.

Garfunkel, along with fellow residents of the committee, was able to select the best candidate among those who presented a bid.

"I found that our discussion during that process was extremely helpful," says Garfunkel. "We were able to in better understand the features being offered by the different vendors, as well as the different costs and options that are available."

Sunshine Renewable Solutions, for their part, says they are thrilled to have been chosen from the other solar installers that were in the competition.

"We've worked hard to build our reputation and spread the love of clean energy and energy independence in the Houston area," says Chandrashekar. "We are ecstatic to help more people go solar by providing them with amazing customer experience at an incredibly low cost."

Those interested in joining the West Houston co-op will be presented with an individualized proposal based on the group rate, which leads to a significant number of dollars saved on the cost.

SUN will be recruiting more members for its East Houston co-op that will close at the end of August.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings